Ventus Thérapeutique annonce l’administration d’un inhibiteur de NLRP3 au...
WALTHAM, Mass. et MONTRÉAL – 3 mai 2024 – (BUSINESS WIRE) – Ventus Thérapeutique inc., une société biopharmaceutique de stade clinique qui utilise ReSOLVETM, sa plateforme exclusive de biologie...
View ArticleVentus Thérapeutique accroît sa présence à Montréal, au Canada, avec...
Les nouvelles installations ultramodernes de 24 000 pieds carrés permettront à Ventus d’être en meilleure posture pour alimenter sa gamme de produits en développement, grâce à la perspective de faire...
View ArticleClik here to view.
Ventus Therapeutics Significantly Expands its Presence in Montreal, Canada...
New 24,000-square-foot state-of-the-art facility will facilitate the build-out of Ventus’ pipeline, enabled by the vision to develop its ReSOLVE platform into a disruptive drug discovery platform...
View ArticleSenior Director, Head of Regulatory Affairs
Waltham (Hybrid) The post Senior Director, Head of Regulatory Affairs appeared first on Ventus Therapeutics.
View ArticleSoftbank’s Cassidy on AI Investments in Healthcare
The post Softbank’s Cassidy on AI Investments in Healthcare appeared first on Ventus Therapeutics.
View ArticleWhy Ventus Therapeutics always puts patients first
The post Why Ventus Therapeutics always puts patients first appeared first on Ventus Therapeutics.
View ArticleHarnessing Water Dynamics for Drug Design with Michael Crackower and Jason Burch
The post Harnessing Water Dynamics for Drug Design with Michael Crackower and Jason Burch appeared first on Ventus Therapeutics.
View ArticleSenior Manager, IT
Waltham (Onsite) The post Senior Manager, IT appeared first on Ventus Therapeutics.
View ArticleVentus Thérapeutique annonce la réussite de l’essai clinique de phase I sur...
Le VENT-03 s’est révélé sûr et bien toléré à toutes les doses évaluées Son profil pharmacocinétique favorable permet d’envisager une administration une fois par jour Le composé a montré une inhibition...
View ArticleClik here to view.
Ventus Therapeutics Announces Successful Completion of Phase 1 Clinical Trial...
VENT-03 was safe and well-tolerated at all tested dose levels Favorable pharmacokinetic profile enables once-daily dosing Demonstrated full target inhibition Initiation of a Phase 2 trial with VENT-03...
View Article